Moreover, the 36-month beta value for TVGN is -0.68. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TVGN is 42.34M and currently, short sellers hold a 4.25% of that float. On June 19, 2025, TVGN’s average trading volume was 942.82K shares.
TVGN) stock’s latest price update
The stock of Tevogen Bio Holdings Inc (NASDAQ: TVGN) has decreased by -1.64 when compared to last closing price of 1.22. Despite this, the company has experienced a -10.45% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-18 that WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associated lymphomas.
TVGN’s Market Performance
Tevogen Bio Holdings Inc (TVGN) has experienced a -10.45% fall in stock performance for the past week, with a 4.35% rise in the past month, and a 5.26% rise in the past quarter. The volatility ratio for the week is 2.72%, and the volatility levels for the past 30 days are at 7.63% for TVGN. The simple moving average for the last 20 days is -6.03% for TVGN stock, with a simple moving average of 2.61% for the last 200 days.
Analysts’ Opinion of TVGN
Many brokerage firms have already submitted their reports for TVGN stocks, with D. Boral Capital repeating the rating for TVGN by listing it as a “Buy.” The predicted price for TVGN in the upcoming period, according to D. Boral Capital is $10 based on the research report published on March 04, 2025 of the current year 2025.
TVGN Trading at 5.15% from the 50-Day Moving Average
After a stumble in the market that brought TVGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.17% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVGN starting from Saadi Ryan H., who sale 1,438,206 shares at the price of $1.23 back on Jun 09 ’25. After this action, Saadi Ryan H. now owns 116,814,453 shares of Tevogen Bio Holdings Inc, valued at $1,768,993 using the latest closing price.
Saadi Ryan H., the Officer of Tevogen Bio Holdings Inc, proposed sale 1,438,206 shares at $1.10 during a trade that took place back on Jun 09 ’25, which means that Saadi Ryan H. is holding shares at $1,582,027 based on the most recent closing price.
Stock Fundamentals for TVGN
Current profitability levels for the company are sitting at:
- -86.75 for the present operating margin
- 0.25 for the gross margin
The net margin for Tevogen Bio Holdings Inc stands at -89.16. The total capital return value is set at 7.4. Equity return is now at value -124.74, with -849.23 for asset returns.
Based on Tevogen Bio Holdings Inc (TVGN), the company’s capital structure generated -0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -7.21. The debt to equity ratio resting at -0.24. The interest coverage ratio of the stock is -9333.73.
Currently, EBITDA for the company is -53.56 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 556.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.35.
Conclusion
To wrap up, the performance of Tevogen Bio Holdings Inc (TVGN) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
